---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-129823"
form_type: "8-K"
ticker: "NVAX"
cik: "0001000694"
company_name: "NOVAVAX INC"
filed_at: "2024-12-18T23:59:59+00:00"
generated_at: "2026-05-29T01:54:09.733736+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Novavax amends Australia COVID vaccine agreement; cancels doses, credits $31M, extends to 2029

## Summary
- Amendment #5 cancels certain COVID vaccine doses scheduled for delivery Q4 2023 through Q4 2025.
- Approximately $31M of advanced payment credited against outstanding invoices and future delivery of ~3M doses.
- Updated delivery schedule allows potential delivery of vaccine through end of 2029.
- Commonwealth granted remedies for missed deliveries, regulatory approval failures, or notification lapses.
- No additional cash payments required for future doses under the amendment.

## SEC filing metadata
- accession: 0001104659-24-129823
- form_type: 8-K
- ticker: NVAX
- cik: 0001000694
- company_name: NOVAVAX INC
- filed_at: 2024-12-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1000694/000110465924129823/0001104659-24-129823-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1000694/000110465924129823/tm2431398d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-129823
- JSON: https://secwatch.observer/filing/0001104659-24-129823.json
- Plain text: https://secwatch.observer/filing/0001104659-24-129823.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.